Lancet Neurology

Article	Citations
The East Asian Parkinson Disease Genomics Consortium	4795
Implications of the KIWE trial for low-income and lower-middle-income countries	732
Multidisciplinary care for amyotrophic lateral sclerosis	718
Dementia diagnosis in the anti-amyloid era	714
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	654
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	518
Correction to Lancet Neurol 2024; 23: 168–77	490
Correction to Lancet Neurol 2022; 21: 42–52	445
Correction to Lancet Neurol 2021; 20: 448–59	421
Lessons and future directions for GBA1-targeting therapies	409
The predictive value and clinical use of the neurological pupillary index – Authors' reply	402
Pseudomedicine for sports concussions in the USA	381
RAB32 mutation in Parkinson's disease	380
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	329
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	327
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	316
Traumatic brain injury research: homogenising heterogeneity	310
Increasing diversity in dementia research	301
New therapies for Pompe disease: are we closer to a cure?	301
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	293
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	281
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	261
Global burden of stroke: dynamic estimates to inform action	252
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	232
A biological classification of Huntington's disease: the Integrated Staging System	215

The relevance of social and commercial determinants for neurological health	212
Management of atherosclerotic extracranial carotid artery stenosis	209
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	199
A chilly tale of dementia	196
Anti-CD19 CAR T cells for refractory myasthenia gravis	196
Trials in intracerebral haemorrhage: a path to success?	186
A study in healing the wounds of trauma	183
Epilepsy syndromes: an essential piece of the puzzle	182
Beyond the modular brain	178
Elia M Pestana Knight	162
Delving into the human mind	161
Albert Kwaku Akpalu	159
A blood test for Alzheimer's disease: a step forward	157
Considering the neurological health needs of LGBTQIA people	154
Safe laboratory management of prions and proteopathic seeds	152
Diana Cejas	151
Gene therapy for X-linked myotubular myopathy: the challenges	148
The prescription of valproate: risk of harm	147
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	146
Correction to Lancet Neurol 2023; 22: 812–25	143
Correction to Lancet Neurol 2022; 21: 284–94	143
Amyotrophic lateral sclerosis from genotoxins alone?	141
A nasal CGRP receptor antagonist for acute migraine therapy	139
Surrogate endpoints for progressive multifocal leukoencephalopathy	135
Parkinson's disease is a recognisable and useful diagnostic entity	130
Development of treatments for Down syndrome	124
Aspiring to restore arm and hand function after stroke	123
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	122
A sensitive portrayal of a controversial condition	119
From stroke awareness to stroke action awareness	117
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	117
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	116
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	116
Movement disorders research in 2021: cracking the paradigm	114
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	112
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	106
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	104
Encephalitis awareness: our ambitious global endeavour	103
Better buildings for elderly people to thrive	101
Expansion of stenting indications in the USA	100
New results for risdiplam in spinal muscular atrophy	100
Neurological infections in 2023: surveillance and prevention	97
Correction to Lancet Neurol 2021; 20: 687–89	97
Jessica Ailani	97
Responsible innovation in neurology	96
The International Brain Initiative: enabling collaborative science	95
Brain health in the Philippines	94
Multiple sclerosis in 2022: old players, new insights	94
Correction to Lancet Neurol 2022; 21: 620–31	92
Correction to Lancet Neurol 2024; 23: 110–22	92

Detection of ionising radiation by the CNS: a case report	89
Cognitive function in people with functional seizures	88
Redefining use of MRI for patients with multiple sclerosis	88
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	87
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	87
Changing multiple-sclerosis-induced thoughts and behaviours	86
Supporting young carers across neurological disorders	85
Learning to be an adult with a disability	84
Major advances in Parkinson's disease over the past two decades and future research directions	83
α-synuclein seed amplification and its uses in Parkinson's disease	81
A proposal for equity neuroscience	81
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	80
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	78
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	78
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	77
Spontaneous intracranial hypotension: searching for the CSF leak	76
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	75
Bastiaan Bloem: power against Parkinson's disease	74
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	74
Sleeping matters	74
Brains are neither pink nor blue but fifty shades of grey matter	73
Living with dementia: seeing the world and adapting to it	73
Eugenia Martínez	73
Headache research in 2023: advancing therapy and technology	72
Correction to Lancet Neurol 2024; 23: 961–62	71
Monitoring brainwaves while gallery visitors view artworks	68
Pragmatic solutions for the global burden of stroke	67
ELEVATEd hope for patients after migraine treatment failure	67
Highlights in traumatic brain injury research in 2024	67
Andrea Schneider	66
Epilepsy research in 2022: clinical advances	65
Detection of awareness after brain injury: time for change	65
A call for optimal oral care in patients with ALS	65
Improving thrombolysis efficiency for acute ischaemic stroke	65
Neuroprotection in acute ischaemic stroke: reasons for optimism?	65
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	64
Expanding the spectrum of type 1 IFN neuroinflammation	64
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	63
Blocking inhibitors of axon growth after spinal cord injury	63
The AfrAbia+plus Parkinson's Disease Genomic Consortium	62
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	61
Targeting auto-antibodies for CIDP: hope and questions	59
The global challenge of hypertension	59
Your After-Visit Summary—May 29, 2042	59
Siddharth Srivastava	59
Thrombolysis before endovascular treatment of tandem lesions	58
Consciousness contextualised	57
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	56
Correction to Lancet Neurol 2024; 23: 344–81	56
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	55
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	54
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	54
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	53
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	53
Diagnosis and treatment of orthostatic hypotension	53
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	53
The torment of needing to know for sure	52
The cultural history of dementia	51
Biomedical research must change as the climate does	51
Geoffrey Manley: TBI guy	50
The bases of remembrance	50
Charles Sherrington's apparatus	50
Neurosurgical lesioning for Tourette syndrome – Authors' reply	49
Major advances in sleep neurology: 2002–22	48
Thank you to The Lancet Neurology's peer reviewers in 2023	47
A brain design for life	46
Early atrial fibrillation rhythm control after stroke	45
Carlayne Jackson: leading the American Academy of Neurology	44
Laquinimod, Huntington's disease, and disease modification	43
Sleep research in 2023: beyond the bare necessities	42
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	42
Angela Dos Santos	41
Changing the landscape of neurological education	39
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	39
A decisive year for the neurological community	39
Correction to Lancet Neurol 2021; 20: 1012–16	38
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	38
Correction to Lancet Neurol 2024; 23: 465–76	38
Advances in amyotrophic lateral sclerosis research in 2022	38
Further support for rituximab in relapsing multiple sclerosis	38

Therapies for myasthenia gravis: FcRn inhibition and beyond	38
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	38
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	37
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	37
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	36
No area of stroke research should be left behind	36
Improving epilepsy diagnosis across the lifespan: approaches and innovations	35
For a dementia diagnosis, clinical acumen must precede biomarkers	35
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	35
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	34
Digital mobility measures to predict Parkinson's disease	34
NfL is ready for translation into paediatrics	34
Frailty and outcome after traumatic brain injury	34
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	33
Teshamae Monteith	33
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	33
The complex pathway between amyloid β and cognition: implications for therapy	33
Sleep matters in anti-LGI1 encephalitis	32
Helping to bring the crisis home	32
Globally advancing neurological education in headache	32
Correction to Lancet Neurol 2021; 20: 615–26	31
Correction to Lancet Neurol 2021; 20: 739–52	31
Revisiting levodopa for advanced Parkinson's disease	30
Friston's theory of everything	30
Correction to Lancet Neurol 2023; 22: 209–17	30
Maria Trojano: advocate for real-world multiple sclerosis studies	29
Neuroscience research in 2024: advances in blood biomarkers and brain omics	29
Nanna Brix Finnerup: integrity and openness to alternatives	29
Global burden of meningitis and implications for strategy	28
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	28
The prescription of valproate: risk of harm	28
RAB32 mutation in Parkinson's disease	27
Neuroscience in the 21st century: circuits, computation, and behaviour	27
Correction to Lancet Neurol 2018; 17: 954–76	27
Blue as an orange	27
Abandon the NAC in α-synuclein	27
Time to get serious about the Global Action Plan on dementia	26
Correction to Lancet Neurol 2024; 23: 344–81	26
Advances in diagnosis, classification, and management of pain in Parkinson's disease	26
Heart health meets cognitive health: evidence on the role of blood pressure	26
Off-label use of aducanumab for cerebral amyloid angiopathy	26
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	25
Nitrous oxide and its neurological harms	25
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	25
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	25
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	25
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	24
CGRP-targeted drugs for migraine: still many uncertainties	24
Amyotrophic lateral sclerosis: a lesson in translation	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Treatment of acute subdural haematoma – Authors' reply	23
Lightning progress in child neurology in the past 20 years	23
Dancing with paper	23
Cerebral amyloid angiopathy criteria: the next generation	22
Vittorio Marchi's staining	22
Treatment of asymptomatic carotid stenosis in SPACE-2	22
With thanks to our peer reviewers in 2022	22
The hidden unity of the mind	21
Addressing neurological burden in the Americas	21
Innovation in the prevention of neurological diseases	21
Transforming amyotrophic lateral sclerosis into a liveable disease	20
A disease-specific therapy in facioscapulohumeral muscular dystrophy	20
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	20
Time to end the stigma of epilepsy	20
Fetal exposure to antiseizure medications: reassurance and concerns	20
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	20
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	20
CGRP blockade and cluster headache: another step forward	20
Correction to Lancet Neurol 2021; 20: 703–04	20
Neurology cannot be embedded in non-communicable disease agendas	20
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	20
A neurotransmitter with a fascinating story	19
The neuropsychiatry of Parkinson's disease: advances and challenges	19
Carpal tunnel syndrome: updated evidence and new questions	19
Carotid revascularisation for carotid stenosis	18
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	18
Differential diagnosis of suspected multiple sclerosis: global health considerations	18
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	18
Chronic effects of inflammation on tauopathies	18
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	18
Cerebral cavernous malformations: to operate or not?	17
Antibiotic neuromuscular junction myasthenic mimetics	17
A genetic basis for the severity of multiple sclerosis	17
Turin as a neuroscience cradle	17
Rigmor Højland Jensen: the headache warrior	16
Changing views of disability	16
A deep scream into the future	16
Alzheimer's disease: a history revisited	16
Kathleen Friel	16
Dealing with the reproducibility crisis in neuroscience from the grassroots	15
Karen Duff: blazing a path in dementia research	15
Limping into oblivion	15
Purkinje cells and their trees	15
Expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	15
Daridorexant for insomnia disorder	15